PASS studies in secondary care (SCEM)2019-03-27T10:07:23+00:00

Project Description

PASS studies in secondary care (SCEM)

One of our key capabilities is undertaking Post-authorisation Safety Studies (PASS) in the hospital setting. These studies follow our Specialist Cohort Event Monitoring (SCEM) methodology, which we created to address the need to provide safety studies in secondary care, specifically for patients who receive initial or all drug treatment in hospitals or hospital outpatient clinics.

Our ability to conduct hospital-based PASS studies and access a network of prescribers in secondary or specialist care is almost unique in the fields of pharmacovigilance and pharmacoepidemiology.

Please contact us to find out more.

For these hospital PASS studies, event data is gathered from medical records of consented patients by hospital prescribers or care teams. A team of DSRU regional study facilitators works with the NIHR CRN (National Institute for Health Research Clinical Research Network) and other networks across the UK to identify secondary or specialist care prescribers in the relevant speciality.

Click the tabs below to find out more:

Our SCEM methodology for studies in secondary care is explained in this short video:


Our SCEM methodology complements the already well-established technique of Modified Prescription Event Monitoring (M-PEM), which we have used to conduct PASS on many medicines prescribed in primary care. By conducting studies in specialist care using SCEM methodology, safety data is collected on patients who may be more complex in terms of underlying disease, co-morbidities and concomitant medications than in the general disease population. We can also monitor prescribing that is transferred from hospital to primary care by obtaining outcome data from both the specialist and the general practitioner.

Hospital patients are identified through a network of specialists and are enrolled into the study only after the clinical decision to prescribe the study drug has been made by the clinician.

Using secondary care medical records, data is collected at treatment initiation and post initiation (the length of the observation period depends on the research question).

In SCEM studies, data on individual patients’ general health, medical history, exposure and outcomes on exposure are captured. SCEM methodology is naturalistic in nature, reflecting clinical practice, is non-interventional, and allows for broad inclusion criteria. SCEM studies can also allow collection of comparative cohorts.

SCEM study process

The SCEM study process is shown below, describing the step-wise approach through which data is collected during a SCEM study:

The DSRU is already conducting SCEM studies across a range of therapeutic areas. Further information on the current active SCEM studies can be found here.

Differences between M-PEM and SCEM

Observational Assessment of Safety in Seroquel (OASIS) SCEM study

The DSRU has recently completed the Observational Assessment of Safety in Seroquel (OASIS) SCEM study. The OASIS study was conducted as part of the risk management plan for the product Seroquel XL. It was designed to examine the short-term (up to 12 weeks) safety and use of quetiapine fumarate in the prolonged-release formulation (Seroquel XL™), along with a comparator group started on the immediate-release formulation, quetiapine IR. Any adult patients in England were eligible for inclusion once the clinical decision had been made to prescribe either the XL or IR preparation as part of normal clinical practice for the clinical diagnosis of schizophrenia and mania associated with bipolar disorder. The DSRU worked in collaboration with the Mental Health Research Network (MHRN) to recruit over 900 patients. The study enabled the systematic collection and reporting of safety data on patients newly initiated on treatment with quetiapine XL within the mental health care trust setting. Data from the OASIS study will be published shortly.

Related Publications

Contact Info

Drug Safety Research Unit Bursledon Hall, Blundell Lane, Southampton, SO31 1AA, U.K.

Phone: +44 (0)23 80 40 86 00

Recent Posts